Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advair Bioequivalence Guidance Falls Short of GSK’s Requests

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.

Advertisement

Related Content

CEO Shifts, Life Cycle Management On Agenda at Morgan Stanley
Advair Generics Likely Lucrative Product For Few That Can Clear High Bar
GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement
Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel